Page 18 - Hal Barron News Today

RUTH SUNDERLAND: Its not a great look for Elliott to park its tanks on lawn of yet another of Britains most prominent female bosses In recent years, three of the companies Elliott has targeted in the UK have been run by women  Walmsley does not trade on her gender and plenty of male bosses have found themselves in the sights of activists, including Barclays CEO Jes Staley  Its possible companies run by women are subliminally perceived as more vulnerable - of course that is not true

Benlysta approved for adult patients with active lupus nephritis in Europe 2 The indication of Benlysta (belimumab) was extended after it significantly improved renal outcomes in those with active lupus nephritis. The European Commission (EC) has approved the expanded use of intravenous (IV) and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN), in addition to systemic lupus erythemat...

EC clears GSKs Benlysta for lupus nephritis 6th May 2021 The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN). The drug is already on the market to treat systemic lupus erythematosus (SLE); this latest approval now provides physicians and patients in Europe with the first and only biologic treatment specifically designed to work...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Investegate announcements from GlaxoSmithKline PLC, Result of AGM

GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. GlaxoSmithKline plc (NYSE: GSK) Operator Good afternoon, ladies and gentlemen. And welcome to the Analyst Call on the GSK First Quarter 2021 Results. I will now hand you over to Iain Mackay, our CFO, who will introduce todays session.SPONSORED: 10 stocks we like better than GlaxoSmithKline When investing geniuses David and Tom Gardn...

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer AnaptysBio earns a $20m milestone payment on approval after originally developing the drug British pharma company GlaxoSmithKline (GSK) has received US approval for its PD-1 inhibitor Jemperli for the treatment of endometrial cancer. The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial can...

GlaxoSmithKline receives US approval for endometrial cancer treatment The trial showed an overall response rate of 42.3% and a duration of response of six months or more for 93.3% of participants GlaxoSmithKline PLC (LON:GSK) said the US Food and Drug Administration (FDA) has approved its treatment for adults with recurrent or advanced endometrial cancer. JEMPERLI (dostarlimab-gxly) is an antibody that blocks the interaction between the PD-1 receptor with two other proteins that suppress the im...

GlaxoSmithKlines Jemperli secures EU approval following US thumbs up Fri, 23rd Apr 2021 16:08 (Alliance News) - GlaxoSmithKline PLC said Friday the European Commission has approved Jemperli for for women with recurrent or advanced dMMR endometrial cancer. Shares in the blue-chip pharma firm were down 0.7% in London on Friday afternoon at 1,339.00 pence each. The EUs approval follows the regulators in the US green-lighting the treatment on Thursday. Dostarlimab, the medical name for Jemperli, i...

Share this article Share this article LONDON, April 22, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the companys Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved t...